Marquee Tech Founders & Investors Join Ultrahuman’s Series A

New faces join the Ultrahuman captable to support global growth plans at Ultrahuman as the waitlist for the app hits 100,000 users in just months

Several prolific tech investors and founders have come together to invest in Ultrahuman, a leading metabolic fitness platform that uses glucose biomarkers to help people optimize their lifestyle. Balaji Srinivasan (ex-Coinbase), Nithin Kamath (founder of Zerodha via Rainmatter) and Preethi Kasireddy (ex-a16z) along with several others have invested in Ultrahuman, the world’s most advanced metabolic fitness platform, in an undisclosed funding amount which will be in addition to their recent series A round.

Others influential leaders include Groww founders (Harsh Jain, Lalit Keshre, Neeraj Singh and Ishan Bansal), Razorpay founder, Harshil Mathur and RazorpayX GM – Shashank Mehta, Akshay BD (founding team Uber India) and Tanmay Bhat (celebrity content creator and investor) as they support Ultrahuman, a metabolic fitness platform that helps people optimize their metabolism via real-time biomarkers like glucose in combination with HRV, sleep and activity insights.

The metabolic health crisis is unarguably one of the largest healthcare crises that exist today. Over a billion people in the world suffer from a metabolic health disorder which contributes to almost 85% of all chronic diseases in the world. By helping people understand how food and exercise affect their metabolic health, people would be able to make informed choices about what they eat and their activity levels. The approach is a geography/diet agnostic way to help people eat and exercise better.

Measuring a powerful biomarker like glucose can reveal so much about how a particular food item affects the user’s metabolic health by measuring the glucose response. This response is unique to an individual and it depends on various factors like their gut microbiome, stress levels, time of the day, food ingredient quality, etc.

Ultrahuman launched with Ultrahuman M1 – a metabolic health tracking platform that provides intelligent nudges based on glucose biomarkers. This helps people optimize their exercise, sleep and nutrition based on deep insights from the platform. The M1 tracks the wearer’s metabolism as they go about their day using a continuous glucose monitoring device. It triggers timely personalized nudges to the user such as alerts to high glucose variability events leading to oxidative stress and suggestions to optimize it via lifestyle interventions.

Nithin Kamath, founder of Zerodha, added: “A big part of living healthier is tracking your diet and eating right, but the problem is doing this accurately is tricky. The approach that Ultrahuman is taking to tackle this problem of improving metabolic fitness by using biomarkers is really interesting. We’re excited to join Mohit and Vatsal on their journey.”

Ultrahuman has raised over $25M to date. Existing investors include Alpha Wave, Steadview Capital, Nexus Venture Partners, Blume Ventures and Utsav Somani’s iSeed fund, and a range of other angel investors including Tiger Global’s Scott Schleifer.

“We’re super excited to welcome some of the world’s foremost founders, investors and biohackers to join our Series A round. The most inspiring aspect of this investment is that most of them are long term users of the platform as well and that strengthens our mission holistically”. said Mohit Kumar, Founder and CEO, Ultrahuman.

Ultrahuman was started by Mohit Kumar and Vatsal Singhal who were also co-founders at Runnr which later merged with India’s largest food delivery service Zomato. Mohit is an avid cyclist, biohacker and Brazilian Jiu-Jitsu enthusiast. Vatsal is a cross-fit enthusiast and a biohacker. Mohit was training at one of the largest MMA Camps in the world (Tiger Muay Thai in Thailand). During his training, he observed athletes train smartly via the usage of data, recovery tools and protocols.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”